JP2010532381A - Ｒａｆキナーゼ阻害剤として有用な複素環式化合物 - Google Patents

Ｒａｆキナーゼ阻害剤として有用な複素環式化合物 Download PDF

Info

Publication number
JP2010532381A
JP2010532381A JP2010515223A JP2010515223A JP2010532381A JP 2010532381 A JP2010532381 A JP 2010532381A JP 2010515223 A JP2010515223 A JP 2010515223A JP 2010515223 A JP2010515223 A JP 2010515223A JP 2010532381 A JP2010532381 A JP 2010532381A
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
mmol
nitrogen
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010515223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532381A5 (enExample
Inventor
ジェニファー コスロー，
ビン グアン，
アレクセイ イシチェンコ，
ジョン ホワード ジョーンズ，
グナナサンバンダム クマールエーベル，
アレクセイ ルゴフスコイ，
ハイルー ペン，
ノエル ポーウェル，
ブライアン レイムンド，
裕子 田中
ジェフリー ベッセルズ，
トーマス ウィン，
チリ シン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2010532381A publication Critical patent/JP2010532381A/ja
Publication of JP2010532381A5 publication Critical patent/JP2010532381A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2010515223A 2007-06-29 2008-06-30 Ｒａｆキナーゼ阻害剤として有用な複素環式化合物 Pending JP2010532381A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94731907P 2007-06-29 2007-06-29
PCT/US2008/068789 WO2009006404A2 (en) 2007-06-29 2008-06-30 Heterocyclic compounds useful as raf kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2010532381A true JP2010532381A (ja) 2010-10-07
JP2010532381A5 JP2010532381A5 (enExample) 2012-07-26

Family

ID=40015666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010515223A Pending JP2010532381A (ja) 2007-06-29 2008-06-30 Ｒａｆキナーゼ阻害剤として有用な複素環式化合物

Country Status (8)

Country Link
US (1) US7968536B2 (enExample)
EP (1) EP2167497A2 (enExample)
JP (1) JP2010532381A (enExample)
CN (1) CN101743242A (enExample)
AU (1) AU2008273017C1 (enExample)
CA (1) CA2694284A1 (enExample)
NZ (1) NZ582349A (enExample)
WO (1) WO2009006404A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106898779A (zh) * 2015-12-21 2017-06-27 斯沃奇集团研究和开发有限公司 用于金属/空气电池的正极和制造该正极的方法
JP2021512861A (ja) * 2018-02-01 2021-05-20 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP2023517519A (ja) * 2020-03-02 2023-04-26 シロナックス・リミテッド フェロトーシス阻害剤ジアリールアミンパラアセトアミド類
US12612388B2 (en) 2020-05-20 2026-04-28 Sironax Ltd. Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
PE20110854A1 (es) * 2008-09-26 2011-12-23 Boehringer Ingelheim Int DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
JP2012514044A (ja) * 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
AR078793A1 (es) * 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
JP5757956B2 (ja) 2009-11-20 2015-08-05 エスケー ケミカルス シーオー．， エルティーディー．Ｓｋ Ｃｈｅｍｉｃａｌｓ Ｃｏ．， Ｌｔｄ． ゴナドトロピン放出ホルモン受容体拮抗剤、その製造方法及びそれを含む医薬組成物
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
IN2014DN07224A (enExample) 2012-02-03 2015-04-24 Basf Se
IN2014DN07954A (enExample) 2012-03-13 2015-05-01 Basf Se
CN102936251A (zh) * 2012-11-05 2013-02-20 上海毕得医药科技有限公司 一种吡咯并[2,3-d]嘧啶衍生物的制备方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2970306A4 (en) * 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
CA2923101A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
CN104761502A (zh) * 2014-01-03 2015-07-08 中国药科大学 苯并咪唑衍生物、其制法及医药用途
US9914698B2 (en) 2014-01-08 2018-03-13 Shanghai Jiaotong University School Of Medicine Stearoyl amino acid salt and preparation method and application thereof
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3246984A4 (en) * 2015-01-14 2018-06-06 Kabushiki Kaisha Toshiba Nonaqueous electrolyte battery and battery pack
JP2019196307A (ja) * 2016-09-15 2019-11-14 武田薬品工業株式会社 複素環アミド化合物
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
CN106928152A (zh) * 2017-03-03 2017-07-07 符爱清 一种尿嘧啶的制备方法
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
CA3065683A1 (en) * 2017-05-30 2018-12-06 Millennium Pharmaceuticals, Inc. Method for producing optically active compound
US11180498B2 (en) 2017-09-27 2021-11-23 The Regents Of The University Of California Substituted pyrrolo[2,3-b]pyridines, pyrazolo[3,4-d]pyrimidines and [1,2,3]triazolo[4,5-b]pyridines as potent antivirals
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
US20230119479A1 (en) 2019-12-10 2023-04-20 Shionogi & Co., Ltd. A histone deacetylase inhibitor having a nitrogen-containing aromatic heterocyclyl group
US11858930B2 (en) * 2020-07-28 2024-01-02 Jazz Pharmaceuticals Ireland Limited Fused bicyclic RAF inhibitors and methods for use thereof
EP4200281A4 (en) 2020-08-18 2024-09-25 Hutchison Medipharma Limited PYRIMIDINONE COMPOUNDS AND THEIR USES
EP4448492B1 (en) 2021-12-17 2026-03-04 Reglagene, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
JP7894535B2 (ja) 2023-02-28 2026-07-23 レグラジーン、インコーポレイテッド 健康状態の治療のための小分子を作製および使用するための組成物および方法
CN117567388B (zh) * 2023-11-14 2024-04-16 济南悟通生物科技有限公司 一种2-乙酰基-5-噻唑甲酸的合成方法
WO2026061401A1 (zh) * 2024-09-19 2026-03-26 生物岛实验室 杂环类化合物及其制备方法和医药用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505193A (ja) * 1996-12-02 2001-04-17 藤沢薬品工業株式会社 ベンズアミド誘導体
JP2004501146A (ja) * 2000-06-19 2004-01-15 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害薬として活性のチオフェン誘導体、その製造方法及びそれを含有する医薬組成物
JP2005511478A (ja) * 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
JP2005525341A (ja) * 2002-02-18 2005-08-25 アストラゼネカ・アクチエボラーグ 化学化合物
WO2006003378A1 (en) * 2004-07-01 2006-01-12 Astrazeneca Ab Azine-carboxamides as anti-cancer agent
WO2006036266A1 (en) * 2004-07-16 2006-04-06 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as aurora kinase inhibitors
WO2006065703A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5840917A (en) * 1995-09-26 1998-11-24 Takeda Chemical Industries, Ltd. Phosphorylamides, their preparation and use
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
CA2240439A1 (en) 1995-12-22 1997-07-03 The Dupont Merck Pharmaceutical Company Novel integrin receptor antagonists
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
JP2000507590A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
US5877182A (en) * 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6017925A (en) * 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
AU6422798A (en) 1997-03-25 1998-10-20 Takeda Chemical Industries Ltd. Stabilized urease inhibitor
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
EP0982030A3 (en) * 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
WO2000038683A1 (en) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
CA2367130A1 (en) * 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
EP1161431A4 (en) 1999-03-10 2002-04-24 Merck & Co Inc 6-AZAINDOL COMPOUNDS AS AN ANTAGONISTS OF THE GONADOTROPIN RELEASE HORMONES
AU2830800A (en) 1999-03-25 2000-10-16 Nissan Chemical Industries Ltd. Chroman derivatives
US6127382A (en) * 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
CA2392576A1 (en) 1999-11-24 2001-05-31 Lingyan Wang .beta.-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa
GB0007245D0 (en) 2000-03-24 2000-05-17 Zeneca Ltd Chemical compounds
EP1296678A2 (en) 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
ATE446093T1 (de) 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
US20040048866A1 (en) * 2002-03-08 2004-03-11 Teodozyj Kolasa Indazole derivatives that are activators of soluble guanylate cyclase
AU2003243318A1 (en) * 2002-05-29 2003-12-19 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
AU2003245669A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
US7361665B2 (en) * 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
EP1400244A1 (en) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
EP1547585A4 (en) 2002-09-25 2008-05-14 Santen Pharmaceutical Co Ltd THERAPEUTIC AGENT AGAINST RHEUMA WITH A BENZAMIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
JP2004161716A (ja) 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
CN102584813B (zh) * 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
JP2004339159A (ja) 2003-05-16 2004-12-02 Sankyo Co Ltd ４−オキソキノリン誘導体を含有する医薬組成物
DE10328999B4 (de) 2003-06-27 2006-08-31 Lanxess Deutschland Gmbh Verfahren zur Herstellung von Metallkomplexpigmenten mit niedriger Dispergierhärte
ES2317031T3 (es) * 2003-07-16 2009-04-16 Janssen Pharmaceutica Nv Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3.
NZ545058A (en) * 2003-07-16 2008-05-30 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
US7189729B2 (en) * 2003-09-30 2007-03-13 Irm Llc Methods and compositions as protein kinase inhibitors
ES2389203T3 (es) 2004-01-12 2012-10-24 Ym Biosciences Australia Pty Ltd Inhibidores de quinasa selectivos
WO2005072733A1 (en) 2004-01-20 2005-08-11 Millennium Pharmaceuticals, Inc. Dyarylurea compounds as chk-1 inhibitors
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
WO2006076442A2 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
CL2008001933A1 (es) * 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505193A (ja) * 1996-12-02 2001-04-17 藤沢薬品工業株式会社 ベンズアミド誘導体
JP2004501146A (ja) * 2000-06-19 2004-01-15 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害薬として活性のチオフェン誘導体、その製造方法及びそれを含有する医薬組成物
JP2005511478A (ja) * 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
JP2005525341A (ja) * 2002-02-18 2005-08-25 アストラゼネカ・アクチエボラーグ 化学化合物
WO2006003378A1 (en) * 2004-07-01 2006-01-12 Astrazeneca Ab Azine-carboxamides as anti-cancer agent
WO2006036266A1 (en) * 2004-07-16 2006-04-06 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as aurora kinase inhibitors
WO2006065703A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106898779A (zh) * 2015-12-21 2017-06-27 斯沃奇集团研究和开发有限公司 用于金属/空气电池的正极和制造该正极的方法
CN106898779B (zh) * 2015-12-21 2020-05-12 斯沃奇集团研究和开发有限公司 用于金属/空气电池的正极和制造该正极的方法
JP2021512861A (ja) * 2018-02-01 2021-05-20 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP2022160635A (ja) * 2018-02-01 2022-10-19 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP7184383B2 (ja) 2018-02-01 2022-12-06 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP7590004B2 (ja) 2018-02-01 2024-11-26 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP2023517519A (ja) * 2020-03-02 2023-04-26 シロナックス・リミテッド フェロトーシス阻害剤ジアリールアミンパラアセトアミド類
JP7807381B2 (ja) 2020-03-02 2026-01-27 シロナックス リミテッド． フェロトーシス阻害剤ジアリールアミンパラアセトアミド類
US12612388B2 (en) 2020-05-20 2026-04-28 Sironax Ltd. Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas

Also Published As

Publication number Publication date
CN101743242A (zh) 2010-06-16
AU2008273017B2 (en) 2013-10-10
AU2008273017C1 (en) 2014-02-13
AU2008273017A1 (en) 2009-01-08
CA2694284A1 (en) 2009-01-08
US7968536B2 (en) 2011-06-28
US20090005359A1 (en) 2009-01-01
WO2009006404A2 (en) 2009-01-08
EP2167497A2 (en) 2010-03-31
NZ582349A (en) 2012-06-29
WO2009006404A3 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
JP5649445B2 (ja) Ｒａｆキナーゼ阻害剤として有用な化合物
AU2008273017C1 (en) Heterocyclic compounds useful as Raf kinase inhibitors
JP2012514044A (ja) Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
US10703748B2 (en) Diazanaphthalen-3-yl carboxamides and preparation and use thereof
KR20210105375A (ko) Cdk 저해제로서의 대환식 화합물, 이의 제조 방법, 및 의약에서의 이의 용도
TW200940544A (en) Inhibitors of PI3 kinase
WO2011123493A1 (en) Substituted pyrrolotriazines as protein kinase inhibitors
HK1143357B (en) Pyrimidine derivatives useful as raf kinase inhibitors
HK1143357A (en) Pyrimidine derivatives useful as raf kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120601

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140312